Nov 18- StemCells Inc said its experimental stem cell therapy improved the functioning and strength of limbs in patients with spinal cord injuries, becoming the second company to report promising data on the treatment for such injuries. StemCells' research centers around the treatment for spinal cord injuries, visual problems that begin at the retina and...» Read More
Ian Read, Pfizer CEO, discusses the pricing and affordability of drugs in the U.S. Read also weighs in on insurance coverage under the Affordable Care Act.
CNBC's Jim Cramer speaks with Robert Hugin, Celgene chairman & CEO, about America's need to build a stronger and more sustainable ecosystem of innovation to continue as the world leader in biomedical innovation.
John Lechleiter, Chairman, President & CEO of Eli Lilly, discusses the company's growth plans as products come off patent and consumers move to generic drugs.
CNBC's Meg Tirrell provides insight on the increase in biotech IPOs, and what to expect from both Cerulean Pharma & Adamas Pharmaceuticals ahead of their IPO pricing Wednesday night.
Despite the recent meltdown in biotech, there are still areas of opportunity within the sector, Citi's Yaron Werber says.
Mallinckrodt is buying drug maker Questcor for $5.6 billion. Barbara Ryan, FTI Consulting managing director, discusses consolidation in pharmaceuticals and shares what stocks she likes in the space.
CNBC's Seema Mody and Dominic Chu look at what's behind today's massive market sell off including biotechs and online retailers.
Heather Bresch Mylan CEO, discusses the concern over capping drug prices and the impact of Obamacare on rising drug costs.
Jason Kolbert, head of health care research at Maxim Group, says that last week's biotech sell-off was not justified as the sector is going through a "paradigm shift" which should results in higher valuations.
Max Herrmann, partner and healthcare research analyst at Oriel Securities, said biotech stocks have gone through a correction after a "phenomenal" rally.
The U.S. government is prohibited by law from negotiating drug prices, reports CNBC's Sheila Dharmarajan.
CNBC's Sheila Dharmarajan discusses the beat down biotech stocks have recently taken and gives 3 reasons why investors should stick with the sector.
CNBC's Sheila Dharmarajan reports why analysts think investors should stick with the biotech sector.
Gilead received a letter from U.S. lawmakers questioning the pricing of its hepatitis c drug Solvadi. Mark Schoenebaum, ISI Health Care Research Group senior managing director, provides perspective.
CNBC's Jim Cramer shares his thoughts on yesterday's Nasdaq selloff and the slumping biotech sector.
Barbara Ryan, FTI Consulting, and Matt Maley, MillerTabek and Company, discuss what has propelled the massive sell-off in the biotech sector.
CNBC's Dominic Chu digs into the battered biotech sector and reveals which stocks are still sliding.
The FMHR traders discuss what warning signs bull investors should be looking for in the stock market and concerns about a biotech bubble.
U.S. lawmakers sent a letter to Gilead requesting information on pricing for its hepatitis c drug Sovaldi. Christopher Raymond of R.W. Baird.
Discussing the market's big reaction to news U.S. lawmakers requested information about Gilead's hepatitis C drug Sovaldi, and which stocks are attractive in the sector, with Geoff Porges, Bernstein Research senior analyst.